Purpose: The treatment of ovarian tumors is carried out with platinum medicine which can lead to incompatibilities or resistances. Thus, it is of great interest to check new medicine suitability for its application. AZD1152 is an Aurora kinase inhibitor predominantly works against Aurora kinase B involved in the chromosome segregation. Cells become polyploidy and reduce the proliferation by this impairment. To investigate whether AZD1152, may play a role in the treatment of ovarian carcinoma we serving it to the cisplatinum-resistant cell line SKOV3 alone and in combination with platinum.
Methods: We look at the proliferation, the ploidy, the phases of cell cycle and the apoptosis activity of the cells.
Results and conclusion: We could show that the combination of both medicines in the preclinical experiment produces a working advantage.